

A two gene-based risk score predicts alcoholic cirrhosis development in males with at-risk alcohol consumption

Rosellina Margherita Mancina,^{1,*}
 Flaminia Ferri,^{2,*} Alessio
 Farcomeni,³ Antonio Molinaro,¹
 Angela Maffongelli,⁴ Monica
 Mischitelli,² Edoardo Poli,²
 Lucia Parlati,⁵ Maria Antonella
 Burza,⁶ Adriano De Santis,² Fabio
 Attilia,² Claudia Rotondo,² Maria
 Margherita Rando,² Maria Luisa
 Attilia,² Mauro Ceccanti,² Stefano
 Ginanni Corradini²

¹Department of Molecular and Clinical Medicine, The Sahlgrenska Academy at the University of Gothenburg, Wallenberg Laboratory, Göteborg, Sweden; ²Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; ³Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy; ⁴Department of General Surgery, Urgency and Organ Transplantation, University Hospital "Paolo Giaccone", University of Palermo, Palermo, Italy; ⁵Hepatology Department, Université Paris Descartes, Cochin Hospital, APHP, Paris, France; ⁶Department of Medicine, Division of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden

*These authors contributed equally to this work

Correspondence: Stefano Ginanni Corradini
 Department of Translational and Precision
 Medicine, Sapienza University of Rome, Viale
 dell'Università 37, 00185 Rome, Italy
 Tel +39 64 997 2086
 Fax +39 64 453 319
 Email stefano.corradini@uniroma1.it

Rosellina Margherita Mancina
 Department of Molecular and Clinical Medicine,
 The Sahlgrenska Academy at the University of
 Gothenburg, Wallenberg Laboratory, Bruna
 Stråket 16, SE-413 45, Göteborg, Sweden
 Email rosellina.mancina@wlab.gu.se

Background: Alcoholic cirrhosis represents 1% of all cause-of-deaths worldwide. Its incidence is higher in males and results from the combination of environmental and genetic factors. Among all the genetic determinants of alcoholic cirrhosis, the patatin-like phospholipase domain protein 3 (*PNPLA3*) rs738409 represents the most widely validated determinant. Recent cross-sectional studies on alcohol abusers identified transmembrane-6 superfamily member 2 (*TM6SF2*) rs58542926, membrane bound O-acyltransferase domain containing 7 (*MBOAT7*) rs641738, and cluster of differentiation 14 (*CD14*) rs2569190 as new genetic risk factors for alcoholic cirrhosis. We aimed to develop a gene-based risk score to predict the incidence of alcoholic cirrhosis in males with at-risk alcohol consumption.

Materials and methods: A total of 416 male at-risk alcohol drinkers were retrospectively examined. The association between alcoholic cirrhosis incidence and *PNPLA3*, *CD14*, *TM6SF2*, and *MBOAT7* variants was tested. Age at onset of at-risk alcohol consumption, age, and body mass index (BMI) were included as covariates to determine the prediction score for alcoholic cirrhosis incidence by evaluating time-dependent receiver operating characteristic curves.

Results: We found that *PNPLA3*, *CD14*, and *TM6SF2* were associated with alcoholic cirrhosis prevalence. *PNPLA3* and *CD14* were also associated with its incidence. The best predictive score formula was (age at onset of at-risk alcohol consumption × 0.1) + (number of *CD14* allele T) + (number of *PNPLA3* allele M) + (BMI × 0.1). A threshold of 7.27 was identified as cutoff for the predictive risk of alcoholic cirrhosis development in 36 years from the onset of at-risk alcohol consumption with 70.1% sensitivity and 78.7% specificity.

Conclusion: We developed the first score for alcoholic cirrhosis prediction that combines clinical and genetic factors.

Keywords: alcoholic cirrhosis, *PNPLA3*, *CD14*, predictive score

Introduction

Alcoholic chronic liver disease, with a prevalence of ~12% in the European and North-American populations, is characterized by a broad spectrum of conditions ranging from simple steatosis to alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma.^{1,2} The alcoholic etiology represents the cause of almost half of all deaths due to cirrhosis and of 1% of all-cause deaths worldwide³ and its specific clinical sequelae and comorbidities are associated with high hospital costs.⁴ Environmental factors, aging, genetic predisposition, and gender play a pivotal role in alcoholic cirrhosis development and progression.^{5,6} The most established environmental factors influencing the susceptibility to chronic alcohol-related liver damage are represented by dose and pattern of alcohol intake, diet, obesity, diabetes, and smoking.⁵ Older age during

chronic ethanol at-risk consumption is also considered a risk factor for more pronounced liver damage.⁶ Indeed, we have shown that despite a lower daily alcohol intake and a shorter duration of at-risk alcohol consumption, the time to cirrhosis development is reduced in alcoholics with a relatively older age at onset of at-risk alcohol consumption, compared with those who started drinking at a younger age.⁷ Although the underlying mechanisms are not completely clear, many putative factors that can increase liver sensitivity to alcohol with age have been described including aging-related increased gut permeability which results in bacterial and pathogen-associated molecular patterns translocation and leads to Kupffer cells activation.⁶

Predisposition to progressive alcoholic chronic liver disease is strongly influenced by genetic heritability.¹ Among all the genetic determinants of liver disease, the patatin-like phospholipase domain protein 3 (*PNPLA3*) rs738409 (I148M) variant has been strongly linked to hepatic damage at different levels (steatosis, necroinflammation, and fibrosis) in both nonalcoholic^{8–13} and alcoholic liver disease in several cross-sectional studies and meta-analyses.^{14–20} Additionally, we previously demonstrated, for the first time in a retrospective analysis of time-dependent data, that the *PNPLA3* I148M variant is independently associated with a shorter time of cirrhosis development in heavy drinkers.⁷ *PNPLA3* is a lipase that promotes the release of triglycerides from intracellular lipid droplets^{21,22} and of retinol from hepatic stellate cells.²³ *PNPLA3* I148M is a loss-of-function variant resulting in accumulation of triglycerides in hepatocytes, accumulation of retinyl palmitate in hepatic stellate cells,^{21–23} and in increased secretion of pro-fibrotic proteins from hepatic stellate cells.²⁴ Recently, a genome-wide association study performed on alcohol abusers with and without cirrhosis identified rs641738 C>T in the membrane bound O-acyltransferase domain containing 7 (*MBOAT7*) and rs58542926 (E167K) in the transmembrane-6 superfamily member 2 (*TM6SF2*) as new loci associated with alcohol-related cirrhosis.²⁵ *MBOAT7* is an enzyme involved in the phospholipid acyl chain remodeling that transfers polyunsaturated fatty acids to lysophosphatidylinositol and other lysophospholipids.²⁶ *TM6SF2* encodes for a protein of unknown function involved in the lipid secretion from the liver.^{27,28} These two loci of susceptibility for alcoholic liver disease have been associated also with the entire spectrum of nonalcoholic fatty liver diseases.^{25,29–33} To date, the role of *PNPLA3*, *TM6SF2*, and *MBOAT7* in liver disease onset and progression has been largely replicated making them the most widely recognized genetic determinant of both alcoholic and nonalcoholic liver disease.

Among other possible genetic predispositions to alcoholic cirrhosis, it has been shown that the rs2569190 (C-159T) variant in the promoter region of the cluster of differentiation 14 (*CD14*) gene is an independent risk factor for alcoholic cirrhosis^{34–38} and decompensated alcoholic cirrhosis,³⁹ when compared to alcoholics, but the role of this polymorphism in the early stages of alcoholic liver disease is not clear.³⁸ Gut-derived endotoxin/lipopolysaccharide intestinal absorption is increased by ethanol overuse and is a powerful Kupffer cell and inflammation activator in the liver via the CD14 endotoxin receptor.⁴⁰

To date, no data are available on whether the *TM6SF2*, *MBOAT7*, and *CD14* variants are associated with a time-dependent risk of alcoholic cirrhosis development.

Alcoholic cirrhosis development and progression is, additionally, strongly influenced by gender. Specifically, females are more susceptible to liver alcohol damage (ie, more damage for the same amount of ethanol consumed) than males.^{5,41,42} This is probably due also to the higher number of Kupffer cells per volume unit in female compared to male liver.⁴³

Although females are more susceptible to liver alcohol damage, males have a higher prevalence of alcoholic cirrhosis, probably due to the higher amount of alcohol they drink compared to females.^{44,45} Thus, since alcoholic cirrhosis is far more prevalent in males and considering the gender-related differences of Kupffer cell density in the liver, we decided to perform our study only in males.

Our aim was to develop, for the first time, a risk score for alcoholic cirrhosis development over time based on combined clinical and genetic factors. We first investigated how genetic factors can interplay with constitutional and environmental features in a population of male at-risk drinkers with or without cirrhosis. Then, for the same population, we developed a gene-based risk score to predict the prevalence over time of alcoholic cirrhosis with at-risk alcohol consumption.

Materials and methods

Study population

A total of 988 consecutive Caucasian male individuals with alcohol disorder and at-risk alcohol consumption from the Department of Clinical Medicine, Policlinico Umberto I, Rome, Italy were recruited between 2005 and 2014. Specifically, 565 male patients from the initial study cohort previously described, which included both genders,⁷ and 423 additional patients recruited during a 4-year extension of the enrollment period were retrospectively examined. At admittance, patients underwent a detailed clinical examination and interview in order to collect accurate, reliable, and

objective medical history about past and current health status and alcohol consumption as previously described.⁷

Briefly, at-risk alcohol consumption was defined as three or more alcohol units per day for at least 5 years and one unit of alcohol was defined as 12 g of ethanol. Lifetime drinking history (LDH) was used to calculate quantitative indices of alcohol consumption patterns, throughout the life span.⁴⁶ In particular, the duration (in years) of at-risk alcohol consumption was calculated from the reported age at onset of at-risk drinking to the end of at-risk alcohol consumption assessed at the first visit or during subsequent follow-up in subjects with still active alcohol intake at first visit. The amount of daily alcohol intake was extrapolated from the LDH and expressed as the average number of alcohol units per day.

The possible presence of cirrhosis was also assessed and the time of cirrhosis diagnosis was reported using data from hospital discharge papers, medical records, physical examination, blood tests, imaging, and endoscopy. Specifically, cirrhosis diagnosis and its timing were based on liver biopsy or on the first occurrence of at least two of the following features: current or past cirrhosis complications (eg, ascites, variceal gastrointestinal bleeding, hepatic encephalopathy), the presence of hyperbilirubinemia, hypoalbuminemia, prolonged international normalized ratio, low platelet count, irregular liver surface at ultrasound/computed tomography, reduced portal vein flow at ultrasound, liver elastometry, gastroesophageal varices at endoscopy. In the absence of a pathological diagnosis or overt cirrhosis, individuals with positivity of only one of the above-mentioned parameters were excluded from the current analyses.

The dry weight to calculate body mass index (BMI) and the presence of diabetes at diagnosis of cirrhosis, or for those patients without a diagnosis of cirrhosis, at first visit were also reported. Patients were asked whether their body weight was stable (changes <5 kg) compared to that at age 25, at the first visit for noncirrhotic patients, and before the diagnosis of cirrhosis in cirrhotic patients. Blood samples were collected after an overnight fast and analyzed for biochemical parameters. DNA was collected from all the individuals.

Individuals with other etiological factors (n=234) of liver disease (ie, hepatitis B and C infection, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, hemochromatosis, Budd–Chiari syndrome), with incomplete LDH data (n=130), incomplete clinical/biochemical data to achieve a diagnosis of alcoholic cirrhosis and/or a defined age at cirrhosis diagnosis (n=132), lack of body weight stability (n=41), or with poor DNA quality (n=35) were excluded from the analyses. Thus, a total of

416 males with at-risk alcohol consumption were analyzed in the current report.

The study was conducted in accordance with the Declaration of Helsinki and approval was obtained from the local ethical committee “Azienda Umberto I.” Every patient provided written informed consent for participation.

Genotyping of *PNPLA3* rs738409, *CD14* rs2569190, *TM6SF2* rs2569190, and *MBOAT7* rs641738 variants

Buffy coat fraction was recovered from whole blood EDTA and DNA extraction was performed using QIAamp® DNA Blood Kit (Qiagen NV, Venlo, the Netherlands) according to the manufacturer's instructions. DNA quantification and suitability for genotyping analysis were checked using the $\Delta\Delta CT$ method coamplifying a sample of known concentration with unknown samples for the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase.

PNPLA3 rs738409, *CD14* rs2569190, *TM6SF2* rs58542926, and *MBOAT7* rs641738 variants were genotyped by TaqMan® genotyping assay (Thermo Fisher Scientific, Waltham, MA, USA). Primers and probes (FAM and VIC labeled) were directly supplied by Thermo Fisher Scientific (TaqMan). Post-PCR allelic discrimination was performed on a CFX384 Real-Time System (Bio-Rad Laboratories Inc, Hercules, CA, USA) by measuring allele-specific fluorescence. For all variants, genotyping was performed in triplicate with 100% concordance between replicates. After quality control, a total of 416 individuals were included in the study. The genotyping success rate for *PNPLA3* rs738409, *CD14* rs2569190, and *TM6SF2* rs58542926 was $\geq 98\%$. Due to the small amount of DNA available for 34 samples, *MBOAT7* rs641738 genotyping was performed in 382 out of 416 individuals (92%).

Statistical analyses

Variables are shown as medians and interquartile ranges. To evaluate the association of alcoholic cirrhosis with the different genetic variants in a cross-sectional fashion, genotype, allele, and categorical variable distributions were compared by chi-squared test. Group differences for continuous variables were evaluated by the Student's *t*-test or the Mann–Whitney *U* test as appropriate, after assessment of normality by the Kolmogorov–Smirnov test. Multivariate binary logistic analyses were performed by introducing as covariates age, BMI, and the presence of diabetes at first visit as known cirrhosis cofactors. Time of progression to cirrhosis was examined by Kaplan–Meier estimates of cumulative incidence rates. The start of follow-up corresponded to onset of at-risk alcohol consumption. Follow-up time refers

therefore to years of exposure to at-risk alcohol consumption. It corresponds to the number of years from age at onset of at-risk alcohol consumption to age at cirrhosis onset or final follow-up without cirrhosis, measuring hence the period of exposure to the pathogenic agent (ie, at-risk alcohol consumption). Both recessive and dominant models were assessed for each gene, and the most informative selected through minimization of the Akaike information criterion (AIC). Missing data were handled using pairwise complete case analysis.

Log-rank test was used to compare differences in cumulative incidence across *PNPLA3* I148M and *CD14* C159T genotypes. Univariate and multivariable Cox regression analyses were used to evaluate the risk of developing cirrhosis. Cox proportional hazards models were used to evaluate the effect of *PNPLA3* I148M and *CD14* C159T genotypes on cirrhosis incidence after adjusting for confounding factors such as age and those present since the beginning of at-risk alcohol consumption (ie, BMI, amount of daily alcohol consumption, and age at onset of at-risk alcohol consumption). The final multivariate Cox regression model was chosen via forward-stepwise selection targeting the AIC. A score to predict alcoholic cirrhosis incidence in 36 years from the onset of at-risk alcohol consumption was calculated by rounding logarithms of HRs at the multivariate analysis, and evaluated using time-dependent receiver operating characteristic (ROC) curves. Also, a score based on the four gene variants under consideration was evaluated, and then discarded since it did not give any improvement in terms of area under the curve (AUC) over the more parsimonious score (which is based on only two of the variants considered).

The score was internally validated by bootstrapping the sample 1,000 times in order to check that the estimated AUC was within the nonparametric bootstrap CI. Analyses were carried out using R version 3.3.3 (R Development Core Team, Vienna, Austria) and *P*-values <0.05 were considered as statistically significant.

Results

Demographic, clinical, and alcohol consumption characteristics of the study population

A total of 416 male individuals with at-risk alcohol consumption were included in the current analyses. Individuals were adults (median age of 47 years), with median age at onset of at-risk alcohol consumption of 22 years, median daily alcohol consumption of 14 alcohol units, and median duration of at-risk alcohol consumption of 21 years.

The study population was stratified based on the presence or absence of cirrhosis into two groups: alcoholic cirrhosis (*n*=90) and noncirrhotic alcohol consumers (NCAC; *n*=326).

Individuals from the NCAC group were younger (45 vs 55 years) and, as expected, healthier with lower BMI, lower diabetes prevalence, and lower aspartate aminotransferase level compared to individuals from the alcoholic cirrhosis group (Table 1). There were no differences between the two groups in the age at onset of at-risk alcohol consumption and the duration of at-risk alcohol consumption, whereas individuals from the NCAC group had higher daily alcohol consumption compared to those with cirrhosis (15 vs 12 alcohol units per day, *P*=0.018).

PNPLA3 I148M, *CD14* C159T, and *TM6SF2* E167K frequency is higher in individuals with cirrhosis

As shown in Table 1, the frequency of *PNPLA3* M allele, *CD14* T allele, and *TM6SF2* K allele was higher in the alcoholic cirrhosis group than in the NCAC group without cirrhosis (*P*<0.001; *P*=0.008 and *P*=0.028, respectively). No differences between the two groups were observed for the *MBOAT7* T allele frequency.

To assess the cross-sectional independent association between *PNPLA3* M allele, *CD14* T allele, or *TM6SF2* K allele and alcoholic cirrhosis, we performed separate multivariate binary logistic analyses for each variant. For all the multivariate analyses, age at first visit, BMI, and the presence of diabetes were included as covariates. *PNPLA3*, *CD14*, and *TM6SF2* were all identified as independent factors associated with alcoholic cirrhosis (Table 2). Specifically, the risk of alcoholic cirrhosis was increased >2-fold for each *PNPLA3* M allele, and ~2-fold increased for each *CD14* T allele. For *TM6SF2*, the risk of cirrhosis was increased only for homozygosity (KK). *TM6SF2* was not associated with alcoholic cirrhosis when a dominant model was run (ie, wild-type vs heterozygous + homozygous).

PNPLA3 I148M and *CD14* C159T genetic polymorphisms are independent risk factors for alcoholic cirrhosis development

As shown in Figure 1A and B, carriers of *PNPLA3* or *CD14* mutant alleles showed an increased incidence of cirrhosis compared to wild-type individuals (log-rank 0.003 and 0.046, respectively). No association between the development of alcoholic cirrhosis and *TM6SF2* or *MBOAT7* was detected (log-rank *P*-value: 0.296 and 0.276, respectively).

To test the time-dependent risk of developing alcoholic cirrhosis, we performed univariate and multivariate Cox regression analyses.

Table 1 Demographic and clinical characteristics according to the presence or absence of cirrhosis

	AC	NCAC	P-value
n	90	326	
Age ^a (years)	55 (49–61)	45 (37–52)	<0.001
BMI (kg/m ²)	26.9 (24.3–30.1)	25.0 (23.1–27.8)	<0.001
Diabetes, ^a n (%)	28 (31.1)	17 (5.7)	<0.001
Age at onset of at-risk alcohol consumption (years)	23 (18–40)	22 (17–29)	0.092
Daily alcohol consumption (unit)	12 (8–16)	15 (10–20)	0.018
Duration of at-risk alcohol consumption (years)	24 (13–32)	20 (12–30)	0.364
INR ^a	1.36 (1.20–1.60)	0.98 (0.92–1.02)	<0.001
Serum bilirubin (mg/dL) ^a	2.01 (1.17–4.11)	0.56 (0.39–0.75)	<0.001
Serum creatinine (mg/dL) ^a	0.83 (0.70–1.00)	0.80 (0.70–0.90)	0.226
Serum AST (U/L) ^a	44 (30–55)	32 (20–55)	<0.001
Serum ALT (U/L) ^a	29 (22–46)	31 (21–52)	0.326
Age at diagnosis of cirrhosis (years)	48 (44–59)	–	–
Child–Pugh class, n (%)^b			
A	31 (34.40)	–	–
B	40 (44.40)	–	–
C	19 (21.10)	–	–
MELD score ^b	13.94 (8.95–17.61)	–	–
PNPLA3, n (%)			
II	20 (22.20)	150 (46.00)	
IM	47 (52.20)	143 (43.90)	
MM	23 (25.60)	33 (10.10)	<0.001
CD14, n (%)			
CC	12 (13.30)	82 (25.20)	
CT	45 (50.00)	170 (52.10)	
TT	33 (36.70)	74 (22.70)	0.008
TM6SF2, n (%)^c			
EE	71 (83.53)	277 (86.00)	
EK	11 (12.94)	44 (13.70)	
KK	3 (3.53)	1 (0.30)	0.028
MBOAT7, n (%)^d			
CC	17 (22.10)	86 (28.20)	
CT	45 (58.40)	163 (53.40)	
TT	15 (19.50)	56 (18.40)	0.555

Notes: Data are expressed as median and interquartile range or as proportions. Genotype and allele frequencies were in Hardy–Weinberg equilibrium ($P > 0.05$). ^aData refer to the first visit. ^bChild–Pugh classes and MELD score were assessed only in individuals with cirrhosis. ^c407 patients (AC, n=85 and NCAC, n=322). ^d382 patients (AC, n=77 and NCAC, n=305). P-values <0.05 shown in bold were considered statistically significant.

Abbreviations: AC, alcoholic cirrhosis; ALT, alanine transferase; AST, aspartate transferase; BMI, body mass index; CD14, cluster of differentiation 14; INR, international normalized ratio; MBOAT7, membrane bound O-acyltransferase domain containing 7; MELD, model for end-stage liver disease; NCAC, noncirrhotic alcohol consumer; PNPLA3, patatin-like phospholipase domain containing 3; TM6SF2, transmembrane-6 superfamily member 2; n, number.

Table 2 Genetic polymorphism associations with alcoholic cirrhosis at multivariate binary logistic regression analyses

	Multivariate analysis		
	OR	95% CI	P-value
PNPLA3 allele M	2.153	1.466–3.162	<0.001
IM vs II	2.004	1.082–3.710	0.027
MM vs II	4.708	2.178–10.177	<0.001
CD14 allele T	1.706	1.160–2.508	0.007
CT vs CC	1.620	0.795–3.530	0.175
TT vs CC	2.894	1.308–6.403	0.009
TM6SF2 allele K	1.465	0.761–2.819	0.253
EK vs EE	1.005	0.456–2.217	0.990
KK vs EE	21.284	1.294–349.985	0.032

Notes: In all multivariate binary logistic regression models, one for each genetic polymorphism, the following variables were included as covariates: age at first visit, body mass index, and diabetes. P-values <0.05 shown in bold were considered statistically significant.

Abbreviations: CD14, cluster of differentiation 14; PNPLA3, patatin-like phospholipase domain containing 3; TM6SF2, transmembrane-6 superfamily member 2.

At the univariate level, BMI, age at onset of at-risk alcohol consumption, PNPLA3 M allele heterozygosity, homozygosity or carriage, and CD14 T allele homozygosity or carriage were found to be risk factors for alcoholic cirrhosis development (Table 3). No association with alcoholic cirrhosis development was detected for the TM6SF2 and the MBOAT7 variants. In particular, TM6SF2 was not associated even under a dominant genetic model (ie, wild-type vs heterozygous + homozygous). When all the four variants were considered together, the risk to develop alcoholic cirrhosis was higher in carriers of the four mutant alleles. However, the risk conferred by having all the four variants was not higher than considering only PNPLA3 M and CD14 T alleles in the same model.

Next, to test whether the association between risk alleles and alcoholic cirrhosis development was independent from other risk factors, we performed two separate multivariate Cox regression analyses using the sum of PNPLA3 M allele and CD14 T allele, or the sum of PNPLA3 M, CD14 T, TM6SF2 K, and MBOAT7 T alleles.

For each Cox regression multivariate analysis, the following variables were included as covariates: age at first visit, BMI, daily alcohol consumption, and age at onset of at-risk alcohol consumption (Table 4). The model with the sum of PNPLA3 M allele and CD14 T allele showed a significant HR of 1.599 that did not improve in the model with the sum of PNPLA3 M, CD14 T, TM6SF2 K, and MBOAT7 T alleles (HR=1.405). Younger age at first visit, higher BMI, and older age at onset of at-risk alcohol consumption were also independent risk factors for alcoholic cirrhosis development in both models.




Figure 1 Cumulative incidence of alcoholic cirrhosis in individuals according to (A) *PNPLA3* 1148M genotype and (B) *CD14* C159T genotype. Alcohol years indicate the duration of at-risk alcohol consumption (daily intake of ≥ 3 alcohol units). It corresponds to the number of years from age at onset of at-risk alcohol consumption to age at cirrhosis onset or final follow-up without cirrhosis, measuring hence the period of exposure to the pathogenic agent. The number at the bottom indicates the number of individuals at risk at the following time points: 0, 10, 20, 30, and 40 years.

Abbreviations: *PNPLA3* II, individuals with two 148I alleles; MM, individuals with two 148M alleles; IM, heterozygotes; *CD14* CC, individuals with two 159C alleles; TT, individuals with two 159T alleles; CT, heterozygotes.

Based on these results, time-dependent ROC curves for alcoholic cirrhosis incidence were calculated using *PNPLA3* and *CD14* allele variants, age at onset of at-risk alcohol consumption, and BMI in order to develop a predictive score for alcoholic cirrhosis development within 36 years from the onset of at-risk alcohol consumption.

The best predictive score was:

$$(\text{age at onset of at-risk alcohol consumption} \times 0.1) + (\text{number of } CD14 \text{ T allele} \times 1) + (\text{number of } PNPLA3 \text{ M allele} \times 1) + (\text{BMI} \times 0.1).$$

The threshold of 7.27 performed well in predicting the risk of alcoholic cirrhosis development, with a sensitivity

of 70.1% and a specificity of 78.7%, whereas the AUC was 75%. The negative predictive value and the positive predictive value were 90.2% and 48.6%, respectively. Calibration was assessed by means of Grønnesby and Borgan test, which confirmed a good calibration ($P=0.182$). The reported AUC was validated internally via the bootstrap. The

bootstrap-estimated 95% CI was 64%–85%, and the reported AUC was well within the CI. Fictitious examples of the use of the score are shown in Table 5 for the purpose of illustration.

Discussion

Chronic alcohol-related liver disease is complex, multifactorial, and multistage with interindividual variations in the progression and outcomes. Alcoholic cirrhosis development depends on environmental and genetic factors and the interplay between them is under investigation.⁴⁷

In the present study, *PNPLA3* I148M and *CD14* C159T variants have been identified as two genetic components independently associated with the time-dependent risk of developing alcoholic cirrhosis in an Italian (Caucasian) population of male at-risk drinkers.

The association between the *PNPLA3* I148M variant and alcoholic cirrhosis has been extensively reported in cross-sectional studies.^{14,17,19,20} In a previous retrospective study, we demonstrated for the first time that the *PNPLA3* I148M variant is also independently associated with the incidence of alcoholic cirrhosis over time.⁷ In the present study, we confirmed the time-dependent association between *PNPLA3* I148M variant and the incidence of alcoholic cirrhosis analyzing a larger population of male alcoholics.

CD14 endotoxin receptor is an essential mediator in inflammatory signaling and Kupffer cell activation in the liver.⁴⁰ The *CD14* C159T variant has been associated with a gain of function, an increased Kupffer cell activation, and inflammatory response.⁴¹ The cross-sectional association between the *CD14* C159T variant and alcoholic cirrhosis has been previously described.^{34–36} In the present study, in agreement with previous studies, using a cross-sectional analysis in male heavy drinkers, we confirmed that the *CD14* C159T variant is independently associated with alcoholic cirrhosis prevalence. Additionally, here we demonstrated,

Table 3 Risk of developing alcoholic cirrhosis: univariate Cox regression

	HR	95% CI	P-value
Age ^a	0.988	0.961–1.016	0.395
BMI (kg/m ²)	1.072	1.026–1.120	0.002
Daily alcohol consumption (unit)	0.983	0.955–1.012	0.251
Age at onset of at-risk alcohol consumption (years)	1.114	1.087–1.142	<0.001
<i>PNPLA3</i> allele M	1.737	1.250–2.414	0.001
IM vs II	2.177	1.202–3.945	0.010
MM vs II	3.052	1.520–6.127	0.002
<i>CD14</i> allele T	1.503	1.080–2.092	0.016
CT vs CC	1.839	0.937–3.607	0.076
TT vs CC	2.406	1.176–4.923	0.016
<i>TM6SF2</i> allele K	1.257	0.795–1.990	0.328
EK vs EE	1.075	0.571–2.024	0.822
KK vs EE	2.204	0.685–7.093	0.185
<i>MBOAT7</i> allele T	1.271	0.937–1.723	0.123
CT vs CC	1.261	0.749–2.121	0.383
TT vs CC	1.615	0.880–2.966	0.122
<i>PNPLA3</i> allele M + <i>CD14</i> allele T	1.537	1.225–1.926	<0.001
<i>PNPLA3</i> allele M + <i>CD14</i> allele T + <i>TM6SF2</i> allele K + <i>MBOAT7</i> allele T	1.428	1.192–1.711	<0.001

Notes: Numbers of individuals (and proportion) in each of the gene allele groups, stratified by AC/NCAC: *PNPLA3* II 20/150 (22/46), IM 47/143 (52/44), MM 23/33 (26/10); *CD14* CC 12/82 (13/25), CT 45/170 (50/52), TT 33/74 (37/23); *TM6SF2* EE 71/277 (84/86), EK 11/44 (13/14), KK 3/1 (3.5/0.3); *MBOAT7* CC 17/86 (22/28), CT 45/163 (58/53), TT 15/56 (20/18). ^aData refer to the first visit. P-values <0.05 shown in bold were considered statistically significant.

Abbreviations: AC, alcoholic cirrhosis; BMI, body mass index; *CD14*, cluster of differentiation 14; *MBOAT7*, membrane bound O-acyltransferase domain containing 7; NCAC, non-cirrhotic alcohol consumer; *PNPLA3*, patatin-like phospholipase domain containing 3; *TM6SF2*, transmembrane-6 superfamily member 2.

Table 4 Risk of developing alcoholic cirrhosis: multivariate Cox regression

	<i>PNPLA3</i> + <i>CD14</i> model			<i>PNPLA3</i> + <i>CD14</i> + <i>TM6SF2</i> + <i>MBOAT7</i> model		
	HR	95% CI	P-value	HR	95% CI	P-value
Age ^a	0.659	0.589–0.738	<0.001	0.679	0.604–0.763	<0.001
BMI (kg/m ²)	1.077	1.028–1.128	0.002	1.075	1.024–1.127	0.003
Daily alcohol consumption (unit)	0.990	0.962–1.018	0.480	0.995	0.969–1.023	0.735
Age at onset of at-risk alcohol consumption (years)	1.596	1.428–1.785	<0.001	1.543	1.375–1.731	<0.001
<i>PNPLA3</i> allele M + <i>CD14</i> allele T	1.599	1.254–2.039	<0.001	–	–	–
<i>PNPLA3</i> allele M + <i>CD14</i> allele T + <i>TM6SF2</i> allele K + <i>MBOAT7</i> allele T	–	–	–	1.405	1.159–1.702	0.001

Notes: ^aData refer to the first visit. In both multivariate Cox regression models the following variables, other than the genetic variants, were included as covariates: age at first visit, BMI, daily alcohol consumption, and age at onset of at-risk alcohol consumption. P-values <0.05 shown in bold were considered statistically significant.

Abbreviations: BMI, body mass index; *CD14*, cluster of differentiation 14; *MBOAT7*, membrane bound O-acyltransferase domain containing 7; *PNPLA3*, patatin-like phospholipase domain containing 3; *TM6SF2*, transmembrane-6 superfamily member 2.

Table 5 Development of a prediction risk score for alcoholic cirrhosis in 10 fictitious patients

	Patient A	Patient B	Patient C	Patient D	Patient E	Patient F	Patient G	Patient H	Patient I	Patient J
Number of <i>PNPLA3</i> and/or <i>CD14</i> risk alleles	0	0	0	1	1	2	2	3	3	4
Age at onset of at-risk alcohol consumption	15	30	45	15	30	15	30	15	30	15
BMI	28	35	28	35	35	35	24	25	18	18
Score	4.3	6.5	7.3	6	7.5	7	7.4	7	7.8	7.3
Predicted AC	No	No	Yes	No	Yes	No	Yes	No	Yes	Yes

Notes: The AC prediction score is calculated for 10 fictitious subjects. When the subjects do not have any *PNPLA3* or *CD14* risk allele, the AC prediction score is below the cutoff (>7.27) for cirrhosis development if either the age at onset of at-risk alcohol consumption is relatively young or the BMI is in the normal range (<25). When one or two risk alleles are present, the AC prediction score is below the cutoff for cirrhosis development if the age at onset of at-risk alcohol consumption is young and the BMI is below the overweight cutoff. In the case of three or four risk alleles, the subjects are always at-risk of cirrhosis development.

Abbreviations: AC, alcoholic cirrhosis; BMI, body mass index; *CD14*, cluster of differentiation 14; *PNPLA3*, patatin-like phospholipase domain containing 3.

for the first time, that the *CD14* C159T variant is independently associated with the development of alcoholic cirrhosis over time.

A recent genome-wide association study on alcoholic liver disease identified new loci of susceptibility to alcoholic cirrhosis on the *TM6SF2* and *MBOAT7* genes.²⁵ The *TM6SF2* (E167K) variant has been widely associated with liver disease prevalence.^{25,29,30,48} In the present study, we confirmed that homozygosity for the minor allele is independently associated with alcoholic cirrhosis using a cross-sectional analysis. However, in the Cox regression analysis, the *TM6SF2* variant was not associated with the time-dependent risk of cirrhosis development. The lack of association in the time-dependent analysis could be due to the low prevalence of homozygosity and insufficient sample size.

The *MBOAT7* variant has been previously associated with both alcoholic and nonalcoholic liver disease.^{25,32,33} However, we did not find any association between the *MBOAT7* variant and alcoholic cirrhosis in both the cross-sectional and longitudinal analyses. This could be due to a lack of power for this variant. The *MBOAT7* variant was the latest polymorphism described to be relevant in this research field and we did not have enough DNA to analyze it in 8% of our study population. This reduced the number of individuals successfully genotyped from 416 to 382. Additionally, the effect size of the *MBOAT7* variant on liver disease has been previously shown to be lower compared to *PNPLA3* and *TM6SF2* variants,³² meaning that a larger number of individuals for each group is needed to detect the association.

On the basis of the genetic associations we found with the time-dependent development of alcoholic cirrhosis, in the present study we developed a score with good accuracy (AUC 75%) to predict the risk of alcoholic cirrhosis onset in

36 years from the beginning of at-risk alcohol consumption, encompassing either genetic or environmental factors. These include the *CD14* C159T and *PNPLA3* I148M variants, BMI, and age at onset of at-risk alcohol consumption. We did not add the other genetic variants in the score because a similar performance was obtained with an extended score. The final score we proposed is parsimonious, therefore, both in the statistical sense (being based on a minimal set of predictors) and in the practical sense (since it does not require assessment of variants of two additional candidate genes).

Concerning environmental factors that can increase the risk of alcoholic cirrhosis, in the present study, we found that BMI also is an independent predictor of alcoholic cirrhosis subsequent development. Higher BMI is a risk factor for hepatic steatosis and steatohepatitis and is considered as a cofactor favoring alcoholic cirrhosis onset.^{5,49–51}

Finally, our results confirmed, as in our previous report,⁷ that a relatively older age at onset of at-risk alcohol consumption is independently associated with alcoholic cirrhosis susceptibility and helps to predict disease development. It is probably referable to the lower resilience of the liver to handle the same levels and patterns of alcohol consumption as in previous life years.^{6,34,35}

Our study is limited by its retrospective design. However, prospective studies on this topic would be too long and unfeasible. A second limitation is that, since in most cases it would have been impossible to know the time of diabetes occurrence, in the present study we did not include the presence of diabetes in the multivariate analyses aimed to investigate associations with the incidence of alcoholic cirrhosis over time and in the prediction score for alcoholic cirrhosis development. As in other genetic studies performed in at-risk drinker populations,^{34,52} our score was

developed for males and does not permit generalization of our findings to the entire population of at-risk drinkers. However, in our previous study, 76% of the entire population of at-risk drinkers consecutively enrolled were males, and this makes our score useful in most of the cases. Although we performed an internal validation, the absence of an independent verification cohort is another limitation of the study and the applicability and reproducibility of the study should be validated in a multicenter cohort. Additionally, very recently a loss-of-function variant in *HSD17B13* (rs72613567) was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis.⁵³ The inclusion of this protective variant in the risk score could improve the performance of similar risk scores in the future.

In conclusion, identifying genetic and environmental candidate factors that confer susceptibility to alcoholic cirrhosis development could potentially inform the clinician on patient management. Our study not only evaluated the weight of the single independent risk factors in alcoholic cirrhosis onset, but also, for the first time, these factors were combined to build a practical and an easy-to-use score. It would be useful, for clinicians, to predict, since the first visit, the risk over time of alcoholic cirrhosis in male patients with at-risk alcohol consumption and to select a population with a high risk to develop cirrhosis in order to plan a patient-tailored therapy (ie, pharmacotherapy for alcohol dependence, dietician counseling, etc).

Future aims are to expand the population study patients to female gender and to different ethnic groups to better delineate how the above-mentioned factors variate and to eventually adjust consistently the alcoholic cirrhosis predicting score.

Acknowledgments

The abstract of this paper was presented at the EASL Annual Meeting in 2017 as a poster with interim findings. The poster's abstract was published in "Poster Abstracts" in the *Journal of Hepatology* (2017, volume 66, issue 1, supplement, page S348; doi.org/10.1016/S0168-8278(17)31030-9). This research was supported by grants of Sapienza, University of Rome and by "Wilhelm and Martina Lundgren Science" Fund.

Author contributions

AF contributed to the statistical analysis. FF, MM, and SGC contributed to the analysis and interpretation of data and drafted the manuscript. RMM, AMo, and MAB performed sample processing and sequencing. FF, AMa, EP, LP, ADS, FA, CR, MR, and MLA collected sample and clinical information. FF, RMM, AF, and SGC contributed to the study concept and

design. MLA, MC, and SGC supervised and oversaw the study. All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work

Disclosure

The authors reports no conflicts of interest in this work.

References

- Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. *Gastroenterology*. 2011;141(5):1572–1585.
- Marcellin P, Kutala BK. Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening. *Liver Int*. 2018;38(Suppl 1):2–6.
- Masarone M, Rosato V, Dallio M, et al. Epidemiology and natural history of alcoholic liver disease. *Rev Recent Clin Trials*. 2016;11(3):167–174.
- Heslin KC, Elixhauser A, Steiner CA. Identifying in-patient costs attributable to the clinical sequelae and comorbidities of alcoholic liver disease in a national hospital database. *Addiction*. 2017;112(5):782–791.
- Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. *Liver Int*. 2006;26(9):1021–1028.
- Magdalen F, Blajszczak C, Nieto N. Key events participating in the pathogenesis of alcoholic liver disease. *Biomolecules*. 2017;7(4):E9–E23.
- Burza MA, Molinaro A, Attilia ML, et al. PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis. *Liver Int*. 2014;34(4):514–520.
- Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet*. 2008;40(12):1461–1465.
- Yuan X, Waterworth D, Perry JR, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. *Am J Hum Genet*. 2008;83(4):520–528.
- Kotronen A, Johansson LE, Johansson LM, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. *Diabetologia*. 2009;52(6):1056–1060.
- Hotta K, Yoneda M, Hyogo H, et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. *BMC Med Genet*. 2010;11:172.
- Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. *Hepatology*. 2010;51(4):1209–1217.
- Romeo S, Sentinelli F, Cambuli VM, et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. *J Hepatol*. 2010;53(2):335–338.
- Tian C, Stokowski RP, Kershenovich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. *Nat Genet*. 2010;42(1):21–23.
- Stickel F, Hampe J, Trépo E, Datz C, Romeo S. PNPLA3 genetic variation in alcoholic steatosis and liver disease progression. *Hepatobiliary Surg Nutr*. 2015;4(3):152–160.
- Chamorro AJ, Torres JL, Mirón-Canelo JA, González-Sarmiento R, Laso FJ, Marcos M. Systematic review with meta-analysis: the I148M variant of patatin-like phospholipase domain-containing 3 gene (PNPLA3) is significantly associated with alcoholic liver cirrhosis. *Aliment Pharmacol Ther*. 2014;40(6):571–581.
- Salameh H, Raff E, Erwin A, et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. *Am J Gastroenterol*. 2015;110(6):846–856.
- Shen JH, Li YL, Li D, Wang NN, Jing L, Huang YH. The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. *J Lipid Res*. 2015;56(1):167–175.

19. Rausch V, Peccerella T, Lackner C, et al. Primary liver injury and delayed resolution of liver stiffness after alcohol detoxification in heavy drinkers with the *PNPLA3* variant I148M. *World J Hepatol*. 2016;8(35):1547–1556.
20. Stickel F, Buch S, Nischalke HD, et al. Genetic variants in *PNPLA3* and *TM6SF2* predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. *Am J Gastroenterol*. 2018.
21. Pirazzi C, Adiels M, Burza MA, et al. Patatin-like phospholipase domain-containing 3 (*PNPLA3*) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. *J Hepatol*. 2012;57(6):1276–1282.
22. Pingitore P, Pirazzi C, Mancina RM. Recombinant *PNPLA3* protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. *Biochim Biophys Acta*. 2014;18414(4):574–580.
23. Pirazzi C, Valenti L, Motta BM, et al. *PNPLA3* has retinyl-palmitate lipase activity in human hepatic stellate cells. *Hum Mol Genet*. 2014;23(15):4077–4085.
24. Pingitore P, Dongiovanni P, Motta BM, et al. *PNPLA3* overexpression results in reduction of proteins predisposing to fibrosis. *Hum Mol Genet*. 2016;25(23):5212–5222.
25. Buch S, Stickel F, Trépo E, et al. A genome-wide association study confirms *PNPLA3* and identifies *TM6SF2* and *MBOAT7* as risk loci for alcohol-related cirrhosis. *Nat Genet*. 2015;47(12):1443–1448.
26. Gijón MA, Riekhof WR, Zarini S, Murphy RC, Voelker DR. Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils. *J Biol Chem*. 2008;283(44):30235–30245.
27. Smagris E, Gilyard S, Basuray S, Cohen JC, Hobbs HH. Inactivation of *Tm6sf2*, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. *J Biol Chem*. 2016;291(20):10659–10676.
28. O'Hare EA, Yang R, Yerges-Armstrong LM, et al. *TM6SF2* rs58542926 impacts lipid processing in liver and small intestine. *Hepatology*. 2017;65(5):1526–1542.
29. Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. *Hepatology*. 2015;61(2):506–514.
30. Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a *TM6SF2* variant that confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet*. 2014;46(4):352–356.
31. Mancina RM, Sentinelli F, Incani M, et al. Transmembrane-6 superfamily member 2 (*TM6SF2*) E167K variant increases susceptibility to hepatic steatosis in obese children. *Dig Liver Dis*. 2016;48(1):100–101.
32. Mancina RM, Dongiovanni P, Petta S, et al. The *MBOAT7-TMC4* variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European Descent. *Gastroenterology*. 2016;150(5):1219–1230.
33. Donati B, Dongiovanni P, Romeo S, et al. *MBOAT7* rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. *Sci Rep*. 2017;7(1):4492.
34. Järveläinen HA, Orpana A, Perola M, Savolainen VT, Karhunen PJ, Lindros KO. Promoter polymorphism of the *CD14* endotoxin receptor gene as a risk factor for alcoholic liver disease. *Hepatology*. 2001;33(5):1148–1153.
35. Martins A, Cortez-Pinto H, Machado M, et al. Are genetic polymorphisms of tumour necrosis factor alpha, interleukin-10, *CD14* endotoxin receptor or manganese superoxide dismutase associated with alcoholic liver disease? *Eur J Gastroenterol Hepatol*. 2005;17:1099–1104.
36. Meiler C, Muhlbauer M, Johann M, et al. Different effects of a *CD14* gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection. *World J Gastroenterol*. 2005;11(38):6031–6037.
37. Nezi V, Deutsch M, Gazouli M, et al. Polymorphisms of the *CD14* genes are associated with susceptibility to alcoholic liver disease in Greek patients. *Alcohol Clin Exp Res*. 2013;37(2):244–251.
38. Zeng T, Zhang C-L, Han X-Y, Zhao S, Xie K-Q. Association between *CD14-159C>T* polymorphisms and the risk for alcoholic liver disease. *Eur J Gastroenterol Hepatol*. 2013;25(10):1–1189.
39. Campos J, Gonzalez-Quintela A, Quinteiro C, et al. The *-159C/T* polymorphism in the promoter region of the *CD14* gene is associated with advanced liver disease and higher serum levels of acute-phase proteins in heavy drinkers. *Alcohol Clin Exp Res*. 2005;29(7):1206–1213.
40. Zeng T, Zhang CL, Xiao M, Yang R, Xie KQ. Critical roles of Kupffer cells in the pathogenesis of alcoholic liver disease: from basic science to clinical trials. *Front Immunol*. 2016;7:538–552.
41. Eagon PK. Alcoholic liver injury: influence of gender and hormones. *World J Gastroenterol*. 2010;16(11):1377–1384.
42. Kirpich IA, McClain CJ, Vatsalya V, et al. Liver injury and endotoxemia in male and female alcohol-dependent individuals admitted to an alcohol treatment program. *Alcohol Clin Exp Res*. 2017;41(4):747–757.
43. Marcos R, Correia-Gomes C, Miranda H, Carneiro F. Liver gender dimorphism: insights from quantitative morphology. *Histol Histopathol*. 2015;30(12):1431–1437.
44. Wilsnack RW, Wilsnack SC, Kristjanson AF, Vogeltanz-Holm ND, Gmel G. Gender and alcohol consumption: patterns from the multinational GENACIS project. *Addiction*. 2009;104(9):1487–1500.
45. Mellinger JL, Shedden K, Winder GS, et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. *Hepatology*. 2018;68(3):872–882.
46. Skinner HA, Sheu WJ. Reliability of alcohol use indices. The lifetime drinking history and the MAST. *J Stud Alcohol*. 1982;43(11):1157–1170.
47. Stickel F, Moreno C, Hampe J, Morgan MY. The genetics of alcohol dependence and alcohol-related liver disease. *J Hepatol*. 2017;66(1):195–211.
48. Sookoian S, Castaño GO, Scian R, et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. *Hepatology*. 2015;61(2):515–525.
49. Yen YH, Chang KC, Tsai MC, et al. Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease. *J Formos Med Assoc*. 2018;117(4):268–275.
50. Romeo S, Sentinelli F, Dash S, et al. Morbid obesity exposes the association between *PNPLA3* I148M (rs738409) and indices of hepatic injury in individuals of European descent. *Int J Obes*. 2010;34(1):190–194.
51. Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. *Hepatology*. 1997;25(1):108–111.
52. Zhang Y, Guo T, Yang F, et al. Single-nucleotide rs738409 polymorphisms in the *PNPLA3* gene are strongly associated with alcoholic liver disease in Han Chinese males. *Hepatol Int*. 2018;12(5):429–437.
53. Abul-Husn NS, Cheng X, Li AH, et al. A protein-truncating *HSD17B13* variant and protection from chronic liver disease. *N Engl J Med*. 2018;378(12):1096–1106.

The Application of Clinical Genetics

Publish your work in this journal

The Application of Clinical Genetics is an international, peer-reviewed open access journal that welcomes laboratory and clinical findings in the field of human genetics. Specific topics include: Population genetics; Functional genetics; Natural history of genetic disease; Management of genetic disease; Mechanisms of genetic disease; Counselling and ethical

issues; Animal models; Pharmacogenetics; Prenatal diagnosis; Dysmorphology. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/the-application-of-clinical-genetics-journal>

Dovepress